Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 13/20 | 0.42 |
| ▸ | PPARA | Q07869 | 6/20 | 0.42 |
| ▸ | PPARD | Q03181 | 6/20 | 0.40 |
| ▸ | GCGR | P47871 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6035581 | 0.98 | PPARG (0.43) | CNR1CNR2PPARGPPARAPPARD | |
| SCHEMBL6035029 | 0.92 | PPARG (0.43) | PPARGPPARAPPARDGCGRFFAR1 | |
| SCHEMBL6035898 | 0.91 | PPARG (0.44) | PPARGPPARAPPARDGCGRFFAR1 | |
| SCHEMBL6036252 | 0.91 | PPARG (0.42) | PPARGPPARAPPARDGCGRFFAR1 | |
| SCHEMBL6036288 | 0.91 | FFAR1 (0.43) | PPARGPPARAPPARDGCGRFFAR1 | |
| SCHEMBL6035612 | 0.91 | PPARG (0.42) | CNR1CNR2PPARGPPARAPPARD | |
| SCHEMBL6035820 | 0.89 | PPARG (0.45) | PPARGPPARAPPARDGCGRFFAR1 | |
| SCHEMBL6035153 | 0.88 | PPARG (0.40) | CNR1CNR2PPARGPPARAPPARD | |
| SCHEMBL6036292 | 0.87 | PPARG (0.42) | PPARGPPARAPPARDGCGR | |
| SCHEMBL6035914 | 0.87 | PPARG (0.43) | PPARGPPARAPPARDGCGRFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | CNR1 804/4885CNR2 1576/4885PPARG 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.